- Natural product: Cannabis (Cannabis sativa)
- Associated study: A phase I study to assess the effect of food on the single dose bioavailability of the THC/CBD oromucosal spray
In Vivo Pharmacokinetics Study
Plasma Concentration of 11-OH-THC when Fed
Table 1
This studies the active metabolite of THC
Results
Table 1
| Sample | Compound measured | Value | Measurement | Study sequence | Additional information | N replicates |
|---|
Experimental Conditions
Randomized crossover
Single dosing
Healthy volunteers
Males
No alcohol drinking
No marijuana use
Nonsmokers
Asian
Black or African American
White
12
Subjects were 19 to 44 years of age with a mean (SD) age of 28.5 (7.55) years. Subjects’ BMI ranged from 18 to 28 kg/m2 with a mean (SD) BMI of 24.8 (2.99) kg/m2 and a mean (SD) bodyweight of 74.02 (11.25) kg at screening. Of the 12 subjects who took part, 8 were white/Caucasian, 2 were black/African–American and 2 were Asian in ethnicity. All subjects were considered healthy at screening and admission and the investigator did not consider any of the reported medical history abnormalities to preclude the participation of any of the subjects who entered into the trial. Additionally, all subjects tested negative for CBs during screening and at admission.
0, 3, 6, 9, 12, 15, 21, 24 h
Drug or Natural Product Administration
Oral
Oromucosal spray
10 mg THC + 10 mg CBD
Fed
Once
Not provided
The THC/CBD spray is a solution containing ethanol, propylene glycol and peppermint oil flavouring for oromucosal use through a sealed pump-action spray device, which was delivered either underneath the tongue, or to the inside of the cheek.
Pharmacodynamics (PD) & Adverse Events
At each visit (during each session) the incidence of adverse events (AEs) was recorded. Laboratory parameters, vital signs, physical examination, oral examination, and checks on concomitant medication were also performed. The reference ranges for vital signs were 34–100 bpm for standing pulse rate, 90–160 mmHg for standing systolic blood pressure and 40–100 mmHg for standing diastolic blood pressure. A clinically significant change was defined as a change from baseline of at least 20 mmHg in systolic blood pressure, of 10 mmHg in diastolic blood pressure and of 10 bpm in pulse rate.
Cardiac disorders
35200000
Fed (no. of events, n=12)
Nervous system disorders:
Dizziness 3
Paraesthesia 1
Somnolence 1
Psychiatric disorders:
Daydreaming 1
Dissociation 0
Euphoric mood 1
Inappropriate effect 1
Metabolism and nutrition disorders: Increased appetite 1
Respiratory, thoracic and mediastinal disorders: Dry throat 1
Injury, poisoning and procedural complications: Procedural site reaction 1
Fasted (no. of events, n=12)
Somnolence 1
Feeling abnormal 1
General disorders and administration site conditions
35800000
Injury, poisoning and procedural complications
36200000
Metabolism and nutrition disorders
36400000
Nervous system disorders
36700000
Psychiatric disorders
36900000
Respiratory, thoracic and mediastinal disorders
37200000
No serious AEs (SAEs) were reported during the course of this study, and all AEs were classified as being mild in severity. All AEs occurring in one or more subjects are presented in Table 3. The most common AE was dizziness in 3 fed subjects. Four AEs were reported by 2 fasted subjects (17%) and 11 AEs were reported by 7 fed subjects (58%), suggesting that THC/CBD spray might be better tolerated by subjects under fasted conditions. However, there was no apparent relationship between the occurrence of AEs and the PKs in these subjects. In the subjects who experienced an AE in the fed state, the Cmax for THC was higher than in the fasted state in 3 subjects, but was lower than in the fasted state in 4 subjects.